0.6532
price up icon14.58%   0.0831
pre-market  시장 영업 전:  .65   -0.0032   -0.49%
loading
전일 마감가:
$0.5701
열려 있는:
$0.5701
하루 거래량:
17.70M
Relative Volume:
2.92
시가총액:
$128.11M
수익:
$52.29M
순이익/손실:
$-134.84M
주가수익비율:
-0.8709
EPS:
-0.75
순현금흐름:
$-117.11M
1주 성능:
-22.70%
1개월 성능:
-35.96%
6개월 성능:
-20.00%
1년 성능:
+12.35%
1일 변동 폭
Value
$0.5554
$0.6582
1주일 범위
Value
$0.5463
$0.88
52주 변동 폭
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
명칭
Sangamo Therapeutics Inc
Name
전화
(510) 970-6000
Name
주소
501 CANAL BLVD., RICHMOND, CA
Name
직원
0
Name
트위터
@sangamotx
Name
다음 수익 날짜
2025-03-17
Name
최신 SEC 제출 서류
Name
SGMO's Discussions on Twitter

SGMO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.6532 128.11M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-13 업그레이드 Truist Hold → Buy
2024-12-10 재확인 H.C. Wainwright Buy
2023-11-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-04-28 다운그레이드 BofA Securities Neutral → Underperform
2023-02-27 업그레이드 Wedbush Neutral → Outperform
2023-01-06 다운그레이드 BofA Securities Buy → Neutral
2022-06-13 재개 Wedbush Neutral
2021-05-04 개시 RBC Capital Mkts Outperform
2021-01-07 재개 Guggenheim Neutral
2021-01-06 개시 Stifel Hold
2020-12-16 재개 H.C. Wainwright Buy
2020-09-08 개시 BofA Securities Buy
2020-07-07 개시 SunTrust Buy
2019-08-26 개시 H.C. Wainwright Buy
2018-11-14 다운그레이드 JP Morgan Overweight → Neutral
2018-11-09 다운그레이드 Guggenheim Buy → Neutral
2018-10-10 개시 Guggenheim Buy
2018-06-20 개시 BofA/Merrill Buy
2017-11-15 업그레이드 Piper Jaffray Neutral → Overweight
2017-06-22 재개 Jefferies Buy
2016-11-01 다운그레이드 Wedbush Outperform → Neutral
2016-10-19 다운그레이드 Piper Jaffray Overweight → Neutral
2015-12-04 개시 Wells Fargo Outperform
2015-10-23 재개 Jefferies Buy
2013-05-03 개시 BioLogic Equity Research Sell
2011-02-23 재확인 JMP Securities Mkt Outperform
2010-07-29 재확인 Wedbush Outperform
2009-10-19 개시 Brean Murray Sell
2009-10-07 재확인 Leerink Swann Outperform
2009-08-25 재확인 JMP Securities Mkt Outperform
모두보기

Sangamo Therapeutics Inc 주식(SGMO)의 최신 뉴스

pulisher
Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025
pulisher
Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot - mySA

Mar 17, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India

Mar 17, 2025
pulisher
Mar 17, 2025

SANGAMO THERAPEUTICS, INC SEC 10-K Report - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates - Investing.com UK

Mar 17, 2025
pulisher
Mar 15, 2025

SANGAMO THERAPEUTICS Earnings Preview: Recent $SGMO Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 15, 2025
pulisher
Mar 13, 2025

SBI Securities Co. Ltd. Invests $28,000 in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference - Zenopa

Mar 12, 2025
pulisher
Mar 09, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript - MSN

Mar 09, 2025
pulisher
Mar 07, 2025

Sangamo Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 07, 2025
pulisher
Mar 06, 2025

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 - WICZ

Mar 06, 2025
pulisher
Mar 04, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough - Simply Wall St

Mar 04, 2025
pulisher
Mar 02, 2025

10 Promising Biotech Stocks to Invest in (March 2025) - Securities.io

Mar 02, 2025
pulisher
Feb 28, 2025

Sangamo Therapeutics (NASDAQ:SGMO shareholders incur further losses as stock declines 15% this week, taking five-year losses to 89% - Yahoo Finance

Feb 28, 2025
pulisher
Feb 23, 2025

Head-To-Head Comparison: Sangamo Therapeutics (NASDAQ:SGMO) versus Novavax (NASDAQ:NVAX) - Defense World

Feb 23, 2025
pulisher
Feb 13, 2025

Isaralgagene civaparvovec (ST-920) for Fabry disease – Fabry... - Fabry Disease News

Feb 13, 2025
pulisher
Feb 11, 2025

Sangamo Therapeutics: Challenging Road Ahead After Pfizer Exit (NASDAQ:SGMO) - Seeking Alpha

Feb 11, 2025
pulisher
Feb 07, 2025

Sangamo reports positive Fabry disease gene therapy results By Investing.com - Investing.com Nigeria

Feb 07, 2025
pulisher
Feb 06, 2025

Sangamo reports positive Fabry disease gene therapy results - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo reports updated data for gene therapy candidate ST-920 - MSN

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit, Improvements in Kidney Function and Favorable Safety Profile - BioSpace

Feb 06, 2025
pulisher
Feb 06, 2025

Sangamo Therapeutics (NASDAQ:SGMO) delivers shareholders stellar 160% return over 1 year, surging 12% in the last week alone - Simply Wall St

Feb 06, 2025
pulisher
Feb 04, 2025

Golden State Equity Partners Has $332,000 Stock Position in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) - MarketBeat

Feb 04, 2025

Sangamo Therapeutics Inc (SGMO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):